Amphotericin B lipid complex adverse reactions: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 13: | Line 13: | ||
|} | |} | ||
The following adverse events have also been reported in patients using ABELCET® in open-label, uncontrolled clinical studies. | The following adverse events have also been reported in patients using ABELCET® in open-label, uncontrolled clinical studies. However, the causal association between these adverse events and ABELCET® is uncertain. | ||
'''Body as a whole''': malaise, weight loss, deafness, injection site reaction including inflammation | '''Body as a whole''': malaise, weight loss, deafness, injection site reaction including inflammation | ||
| Line 19: | Line 19: | ||
'''Allergic''': bronchospasm, wheezing, [[asthma]], anaphylactoid and other allergic reactions | '''Allergic''': bronchospasm, wheezing, [[asthma]], anaphylactoid and other allergic reactions | ||
'''Cardiopulmonary:''' cardiac failure, pulmonary edema, shock, myocardial infarction, [[hemoptysis]], [[tachypnea]], [[thrombophlebitis]], pulmonary embolus, cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation. | '''Cardiopulmonary:''' cardiac failure, pulmonary edema, [[shock]], myocardial infarction, [[hemoptysis]], [[tachypnea]], [[thrombophlebitis]], pulmonary embolus, cardiomyopathy, [[pleural effusion]], arrhythmias including ventricular fibrillation. | ||
'''Dermatological:''' [[maculopapular rash]], [[pruritus]], [[exfoliative dermatitis]], [[erythema multiforme]] | '''Dermatological:''' [[maculopapular rash]], [[pruritus]], [[exfoliative dermatitis]], [[erythema multiforme]] | ||
'''Gastrointestinal:''' acute liver failure, hepatitis, jaundice, melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, diarrhea, hepatomegaly, cholangitis, cholecystitis | '''Gastrointestinal:''' acute liver failure, [[hepatitis]], [[jaundice]], melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, diarrhea, hepatomegaly, [[cholangitis]], [[cholecystitis]] | ||
'''Hematologic:''' coagulation defects, [[leukocytosis]], blood | '''Hematologic:''' coagulation defects, [[leukocytosis]], blood dyscrasias including [[eosinophilia]] | ||
'''Musculoskeletal:''' [[myasthenia]], including bone, muscle, and joint pains | '''Musculoskeletal:''' [[myasthenia]], including bone, muscle, and joint pains | ||
Latest revision as of 05:47, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The total safety data base is composed of 921 patients treated with ABELCET® (5 patients were enrolled twice and counted as separate patients), of whom 775 were treated with 5 mg/kg/day. Of these 775 patients, 194 patients were treated in four comparative studies; 25 were treated in open-label, non-comparative studies; and 556 patients were treated in an open-label, emergency-use program. Most had underlying hematologic neoplasms, and many were receiving multiple concomitant medications. Of the 556 patients treated with ABELCET®, 9% discontinued treatment due to adverse events regardless of presumed relationship to study drug.
In general, the adverse events most commonly reported with ABELCET® were transient chills and/or fever during infusion of the drug.[1]
 |
The following adverse events have also been reported in patients using ABELCET® in open-label, uncontrolled clinical studies. However, the causal association between these adverse events and ABELCET® is uncertain.
Body as a whole: malaise, weight loss, deafness, injection site reaction including inflammation
Allergic: bronchospasm, wheezing, asthma, anaphylactoid and other allergic reactions
Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction, hemoptysis, tachypnea, thrombophlebitis, pulmonary embolus, cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation.
Dermatological: maculopapular rash, pruritus, exfoliative dermatitis, erythema multiforme
Gastrointestinal: acute liver failure, hepatitis, jaundice, melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, diarrhea, hepatomegaly, cholangitis, cholecystitis
Hematologic: coagulation defects, leukocytosis, blood dyscrasias including eosinophilia
Musculoskeletal: myasthenia, including bone, muscle, and joint pains
Neurologic: convulsions, tinnitus, visual impairment, hearing loss, peripheral neuropathy, transient vertigo, diplopia, encephalopathy, cerebral vascular accident, extrapyramidal syndrome and other neurologic symptoms
Urogenital: oliguria, decreased renal function, anuria, renal tubular acidosis, impotence, dysuria
Serum electrolyte abnormalities: hypomagnesemia, hyperkalemia, hypocalcemia, hypercalcemia
Liver function test abnormalities: increased AST, ALT, alkaline phosphatase, LDH
Renal function test abnormalities: increased BUN
Other test abnormalities: acidosis, hyperamylasemia, hypoglycemia, hyperglycemia, hyperuricemia, hypophosphatemia
To report SUSPECTED ADVERSE REACTIONS, contact Sigma-Tau Pharmaceuticals, Inc. at 1-888-393-4584 or by email at drugsafety@sigmatau.com or contact the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.
References
Adapted from the FDA Package Insert.